# Widely accessible prognostication using medical history for fetal

- 2 growth restriction and small for gestational age in nationwide insured
- 3 **women**

1

- 4 Herdiantri SUFRIYANA, MD PhD;<sup>1,2</sup> Fariska Zata AMANI, MD;<sup>3</sup> Aufar Zimamuz
- 5 Zaman AL HAJIRI, MD; 4 Yu-Wei WU, PhD; 1,5 Emily Chia-Yu SU, PhD. 1,5,6, \*
- 6 <sup>1</sup> Graduate Institute of Biomedical Informatics, College of Medical Science and
- 7 Technology, Taipei Medical University, 250 Wu-Xing Street, Taipei 11031, Taiwan
- 8 <sup>2</sup> Department of Medical Physiology, Faculty of Medicine, Universitas Nahdlatul
- 9 Ulama Surabaya, 57 Raya Jemursari Road, Surabaya 60237, Indonesia
- 10 Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Nahdlatul
- 11 Ulama Surabaya, 57 Raya Jemursari Road, Surabaya 60237, Indonesia
- <sup>4</sup> Faculty of Medicine, Universitas Nahdlatul Ulama Surabaya, 57 Raya Jemursari Road,
- 13 Surabaya 60237, Indonesia
- <sup>5</sup> Clinical Big Data Research Center, Taipei Medical University Hospital, 250 Wu-Xing
- 15 Street, Taipei 11031, Taiwan
- <sup>6</sup> Research Center for Artificial Intelligence in Medicine, Taipei Medical University,
- 17 250 Wu-Xing Street, Taipei 11031, Taiwan
- \* Corresponding author: Graduate Institute of Biomedical Informatics, College of
- 19 Medical Science and Technology, Taipei Medical University, 250 Wu-Xing Street,
- 20 Taipei 11031, Taiwan. Phone: +886-2-66382736 ext. 1515. Email address:
- 21 emilysu@tmu.edu.tw.

#### Abstract

22

44

23 **Objectives:** Prevention of fetal growth restriction/small for gestational age is adequate 24 if screening is accurate. Ultrasound and biomarkers can achieve this goal; however, both 25 are often inaccessible. This study aimed to develop, validate, and deploy a prognostic 26 prediction model for screening fetal growth restriction/small for gestational age using 27 only medical history. **Methods:** From a nationwide health insurance database 28 (n=1,697,452), we retrospectively selected visits of 12-to-55-year-old females to 22,024 29 healthcare providers of primary, secondary, and tertiary care. This study used machine 30 learning (including deep learning) to develop prediction models using 54 medical-31 history predictors. After evaluating model calibration, clinical utility, and explainability, 32 we selected the best by discrimination ability. We also externally validated and 33 compared the models with those from previous studies, which were rigorously selected 34 by a systematic review of Pubmed, Scopus, and Web of Science. Results: We selected 35 169,746 subjects with 507,319 visits for predictive modeling. The best prediction model 36 was a deep-insight visible neural network. It had an area under the receiver operating 37 characteristics curve of 0.742 (95% confidence interval 0.734 to 0.750) and a sensitivity 38 of 49.09% (95% confidence interval 47.60% to 50.58% using a threshold with 95% 39 specificity). The model was competitive against the previous models in a systematic 40 review of 30 eligible studies of 381 records, including those using either ultrasound or 41 biomarker measurements. We deployed a web application to apply the model. 42 Conclusions: Our model used only medical history to improve accessibility for fetal 43 growth restriction/small for gestational age screening. However, future studies are

45 **Key words:** fetal growth restriction, small for gestational age, machine learning, deep

warranted to evaluate if this model's usage impacts patient outcomes.

learning, electronic health records, risk prediction.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Fetal growth restriction (FGR) and small for gestational age (SGA) are two terms of a single condition with the same diagnostic criterion in principle but different measures in practice. This condition is the second leading cause of preventable perinatal deaths. 2 The prevention method depends on FGR/SGA predictions with a clinically acceptable predictive performance.<sup>3</sup> However, most settings lack accessibility to predictors in existing prediction models.<sup>4</sup> A pregnancy with FGR likely results in delivering low-birth-weight infants,<sup>5</sup> an indirect cause of neonatal deaths. <sup>6-8</sup> Neonatal mortality rates varied from 20 to 30 deaths per 1000 live births worldwide in 2013. Low-birth-weight infants also need to spend time in a neonatal intensive care unit. 10 But, this requires high costs and is a limited resource in many countries. 11,12 Prevention of FGR/SGA may reduce neonatal mortality and associated costs. <sup>13</sup> Several preventive strategies were found to be effective for FGR/SGA;<sup>14</sup> yet, this intervention needs a screening method with a good predictive performance.<sup>3</sup> Since a low-cost method such as symphysis fundal height was not recommended by a Cochrane review, mainly due to low sensitivity (~17%), there is a trend to employ either ultrasound or biomarker measurements for FGR/SGA screening. <sup>15</sup> Nonetheless, these methods are inaccessible in resource-limited settings. 15,16 Meanwhile, there was an association detected of FGR/SGA with a woman's medical history. <sup>17</sup> Because a health insurance claim database abundantly records medical histories, this allows proactive screening for FGR/SGA, particularly in countries with universal health coverage. <sup>18</sup> Screening by medical history is also independent of the number of pregnancy

consultations on which FGR detection depends (hazard ratio 1.15, 95% confidence

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

4

interval [CI] 1.05 to 1.26). 19 However, studies have yet to develop a screening method for FGR/SGA using only medical history. Prognostic predictions of FGR/SGA using medical histories can be either a prediction model for use in resource-limited settings or a preliminary prediction model before ordering ultrasound and biomarker measurements. Both statistical and computational machine learning can predict pregnancy outcomes in advance.<sup>20</sup> including deep learning and those using only medical history. <sup>20,21</sup> We aimed to develop, validate, and deploy a prognostic prediction model for screening FGR/SGA using only medical history in nationwide insured women. **Materials and Methods** Report completeness of this study was according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) checklist (Appendix A).<sup>22</sup> We followed a protocol with the same software and hardware (Tables B1-B3, C1),<sup>23</sup> except those stated otherwise. This study was under a single project that compared a deep-insight visible neural network (DI-VNN) to other machine learning algorithms to predict several outcomes in medicine. The Taipei Medical University Joint Institutional Review Board exempted this project from the ethical review (TMU-JIRB no.: N202106025). Study design and data source We applied a retrospective design to select subjects from a public dataset version 2 (August 2019;<sup>24</sup> access approval no.: 510/PPID/1223) of a nationwide health insurance

database in Indonesia. The dataset was a cross-sectional, random sampling of ~1% of

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

outcome to a censored one.

insurance holders within 2 years up to 2016. This sampling included all affiliated healthcare providers (n=22,024) at all levels (i.e., primary, secondary, and tertiary care). The inclusion criteria were females aged 12 to 55 years who had visited primary, secondary, or tertiary care facilities. All visits afterward were exprotocolcluded if a woman was pregnant and had a delivery. If a woman became pregnant twice within the dataset period, then different identifiers were assigned to differentiate the pregnancy periods of that woman. To determine a delivery, we used several codes of diagnoses and procedures (Table C2). This study developed a prediction model for detecting in advance a visit by a subject who would be diagnosed with either FGR or SGA. We pursued to achieve an acceptable sensitivity at 95% specificity but using more-accessible predictors. Nevertheless, we compared our prediction models with those from previous studies selected by systematic review methods to evaluate if our predictive modeling was successful. Since there were different policies in choosing a prediction threshold (e.g., that at 90% vs. 95% specificity), the comparison was conducted using receiver operating characteristics (ROC) curves and the area under the ROC curve (AUROC). The event outcome definition in this study utilized the International Classification of Disease version 10 (ICD-10) codes. These were codes preceded by either O365 (maternal care for known or suspected fetal growth) or P05 (disorders of newborns related to slow fetal growth and fetal malnutrition). Both codes indicating FGR and SGA were assigned with those respectively for mothers and fetuses/newborns. A nonevent outcome was assigned if the end of pregnancy was identified within the dataset period by the codes for determining delivery. Otherwise, we assigned an

### Statistical analysis

and placenta previa.

We developed five models using different algorithms and hyperparameter tuning, as described in the protocol. <sup>22</sup> The first applied ridge regression (RR). The second to fourth models used 54 candidate predictors transformed into principal components (PCs). We applied three algorithms using these PCs: (1) elastic net regression (PC-ENR); (2) random forest (PC-RF); and (3) gradient boosting machine (PC-GBM). The fifth model was a deep-insight visible neural network (DI-VNN). However, unlike the protocol, <sup>22</sup> we did not limit this model to only 22 of 54 candidate predictors, which had a false discovery rate of ≤5% based on differential analyses with Benjamini-Hochberg multiple testing corrections. Instead, we used all 54 candidate predictors considering the feasibility of constructing the data-driven network architecture. In addition, all model recalibration was by either a logistic regression or a general additive model using locally weighted scatterplot smoothing. The recalibration procedure also differed from the protocol. <sup>22</sup> This is because the models only sometimes resulted in a wide range of predicted probabilities, as required for recalibration. Unlike the protocol, we chose 100

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

repetitions for bootstrapping, considering the sample size of this study compared to that of the protocol. Details on model development and validation are described in Table B2. For deployment, this model will predict the outcome each time an insured woman visits a healthcare provider. We provided the best model in this study as a web application. A user is only required to upload a comma-separated value (.csv) file consisting a two-column table. It includes column headers of "admission date" (vvvvmm-dd) and "code" (ICD-10 code at discharge) from previous to current visits. We computed an uncertainty interval (i.e., 95% confidence interval, CI) for each evaluation metric. This interval inference used subsets of an evaluated set, resampled by bootstrapping and cross-validation. All analytical codes were publicly shared (see "Data sharing statement"). The selection of latent candidate predictors in the first model applied inverse probability weighting for the multivariate analyses, according to the protocol.<sup>22</sup> Results were also compared to those by outcome regression. We selected a latent candidate predictor if its association with the outcome had an interval of odds ratio (OR) excluding a value of 1. The evaluation metrics were those for assessing the models' calibration, utility, explainability, and discrimination. To evaluate the model calibration, we assessed (1) a calibration plot with a regression line and histograms of either event or nonevent distribution of the predicted probabilities; (2) the intercept and slope of the linear regression; and (3) the Brier score. We measured the clinical utility using a decision curve analysis by comparing the net benefits of a model with those if we treated all predictions as either positive (i.e., treat all) or negative (i.e., treat none). Clinicians (i.e.,

FZA and AZZAH) assessed the explainability. They were given counterfactual

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

8

Figure 1

householder (Table C7). Differences in the latent candidate predictors implied their

Table 1

associations with the outcome.

#### **Association tests**

186

187

188

189

190

191

192

193

194

195

196

197

199

200

201

202

203

204

205

206

To select latent candidate predictors in the prediction models, their associations with the outcome were verified by multivariate analyses using inverse probability weighting (see Table C8 for comparison to those verified by logistic regression). We adjusted associations using confounders (Table 2; Figures B1-B9). Significant associations persisted after adjustment, in which the effect sizes only slightly changed. However, since the effect sizes were small, the selected latent candidate predictors might be weak predictors for the prediction models.

207 Table 2

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

The best prediction model Only three of the five models were approximately well-calibrated (Figure 2a): the PC-ENR, PC-GBM, and DI-VNN. Among these models, the PC-GBM was considerably the best-calibrated (intercept -0.00098, 95% CI -0.13098 to 0.12902; slope 0.95, 95% CI 0.46 to 1.44; Brier score 0.0063). Nevertheless, the downstream analyses evaluated all of the well-calibrated models. Figure 2 The net benefits of these models were higher than those of either the treat-all or treat-none prediction (Figure 2b). It also applied to those using a threshold of 95% specificity. With this threshold, we found the DI-VNN to be the best model in terms of clinical utility with a net benefit of 0.0023 (95% CI 0.0022 to 0.0024). Regarding model explainability, both clinicians chose the DI-VNN among the well-calibrated models. They considered the plausibility of the top-five predictors according to the counterfactual probabilities (Table 3). One of the top predictors in the DI-VNN, i.e., severe preeclampsia, could change most of the predicted events into nonevents (PN 98.57%, 95% CI 98.5% to 98.63%) if the predictors were changed from positive to negative. Most of the nonevents were also changed into events (PS 2.08%, 95% CI 2.07% to 2.09%) if the predictors were changed from negative to positive. In addition, we also show the models' parameters (Tables C9-C14) and all counterfactual probabilities (Tables C15-C17). Table 3 The discrimination ability differed among the well-calibrated models according

to the ROC curves (Figure 3) and AUROCs (Figure 4). Based on the internal calibration

split, we identified that the best model was also the DI-VNN (AUROC 0.742, 95% CI 0.734 to 0.750; sensitivity 49.09%, 95% CI 47.60% to 50.58%). Using external validation, the AUROC of the DI-VNN (0.561, 95% CI 0.558 to 0.564) was considerably robust (i.e., the 95% CI >0.5).

Figure 3

231

232

233

234

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

Furthermore, we compared the best model with those from previous studies. Only three studies fulfilled the eligibility criteria from three literature databases within the last 5 years. All of the studies were systematic reviews. Thus, we also searched eligible articles in the systematic reviews, including those published more than 5 years earlier. This step resulted in 381 records, including the three systematic reviews (Figure B10). We included 27 studies (Tables D1, D2) of these records for the meta-analysis. These studies used only a training set; thus, the evaluation metrics were extracted only from the training set. We categorized these studies based on the publication year such that the trend of the predictor modalities could be differentiated. By estimation, the DI-VNN was outperformed by those using ultrasound only from previous studies published from 1992 to <2002 (Figures 3, 4, Table C18). This finding was according to the sensitivity. However, those models were developed using smaller sample sizes (Figure 3) and were only evaluated using training sets (Figure 4). We also identified the latter issue for the previous model, which used both ultrasound and biomarkers but without other predictors, from a previous study published in a later year. Meanwhile, based on the AUROC using external validation splits, the DI-VNN was also estimated to outperform the previous models, which used either ultrasound or biomarkers without or with other

predictors, from previous studies published from 2002 to 2016 (i.e., the two latest groups of publication years).

Figure 4

Eventually, we chose the DI-VNN to predict FGR/SGA in advance among 12-to-15-year-old females that visited primary, secondary, or tertiary care. Similar to the development pipeline of the prediction model, only a pregnant woman was eligible for the use of the DI-VNN to compute a predicted probability of FGR/SGA. We deployed the DI-VNN as a web application (<a href="https://predme.app/fgr\_sga/">https://predme.app/fgr\_sga/</a>). It can be used for future use or independent validation of the DI-VNN because it is open access.

#### **Discussion**

We developed, validated, and deployed a web application to predict FGR/SGA in advance using the medical history of diagnoses and procedures. The prediction model for the web application was the DI-VNN, chosen among five prediction models in this study, using only an internal validation set. However, external validation also demonstrated the robustness of the DI-VNN's predictive performance. It was also comparable to those developed in the previous studies, which used ultrasound and biomarkers without or with other predictors.

For predicting FGR/SGA, the previous models, as systematically reviewed in this study (Table D2), mainly required either ultrasound or biomarker measurements and a specific range of gestational ages. The models included those which were competitive with the DI-VNN based on the AUROC by internal validation (Figure 4). The models were by Shlossman, et al <sup>27</sup> (nos. 17e, 17f, and 17b), Bednarek, et al <sup>28</sup> (no. 21), Valiño, et al <sup>29</sup> (no. 16), and Poon, et al <sup>30</sup> (no. 24). Conversely, external validation

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

estimated that the DI-VNN would outperform the other previous models with the similar requirements. The models were by Bano, et al <sup>31</sup> (no. 22a), Carbone, et al <sup>32</sup> (no. 15c), Leung, et al <sup>33</sup> (no. 8c), and Krantz, et al <sup>34</sup> (no. 9b). Furthermore, evaluation of the previous models used training sets only, in which the predictive performances might have been overoptimistic. The DI-VNN required neither ultrasound nor biomarkers without or with other predictors. We would expect wider access for FGR/SGA predictions as either (1) a prediction model for use in resource-limited settings or (2) a preliminary prediction model before ordering advanced predictor measurements. However, the DI-VNN needs an impact study to evaluate its effect on patient outcomes in various settings. An effective prevention for FGR was given by  $\leq 16$  weeks' gestation.<sup>3</sup> To widen prevention time window, more clinical trials are needed. These studies are more efficient if they are conducted among pregnant women with higher risk, as predicted by the DI-VNN. Since it did not require a specific range of gestational ages, the DI-VNN opens more opportunities to conduct such trials. One of the strengths of this study were no requirements from our models, including the DI-VNN, for either ultrasound or biomarker measurements to predict FGR/SGA in advance. We could apply our models to a general population of pregnant women. Furthermore, our model did not require a specific gestational age range for computing the predicted probability. Unlike previous studies, we also conducted external validation to estimate the future predictive performance of the DI-VNN. However, we also identified several limitations of this study. The predictive performance of the best model, i.e., the DI-VNN, was considerably moderate according to the AUROC as was the sensitivity at 95% specificity using an internal validation set.

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

SGA, small for gestational age

14

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

(FGR)/small for gestational age (SGA).

15

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

importance.

16

Table C10. Principal-component elastic net regression (PC-ENR) weights.

Table C11. Principal-component gradient boosting machine (PC-GBM) variable

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

17

ensuring that questions related to the accuracy or integrity of any part of the work are

appropriately investigated and resolved.

395

396

397

The authors report no conflict of interest.

#### Acknowledgments

- 398 The BPJS Kesehatan in Indonesia permitted access to the sample dataset in this study.
- 399 This study was funded by: (1) the Postdoctoral Accompanies Research Project from the
- 400 National Science and Technology Council (NSTC) of Taiwan (grant no.: NSTC111-
- 401 2811-E-038-003-MY2), and the Lembaga Penelitian dan Pengabdian kepada
- 402 Masyarakat (LPPM) Universitas Nahdlatul Ulama Surabaya of Indonesia (grant no.:
- 403 161.4/UNUSA/Adm-LPPM/III/2021) to Herdiantri Sufriyana; and (2) the Ministry of
- 404 Science and Technology (MOST) of Taiwan (grant nos.: MOST110-2628-E-038-001
- and MOST111-2628-E-038-001-MY2), and the Higher Education Sprout Project from
- 406 the Ministry of Education (MOE) of Taiwan (grant no.: DP2-111-21121-01-A-05) to
- 407 Emily Chia-Yu Su. These funding bodies had no role in the study design; in the
- 408 collection, analysis, and interpretation of data; in the writing of the report; or in the
- decision to submit the article for publication.

## 410 **Data Statements**

- 411 The social security administrator provided the data for health or badan penyelenggara
- jaminan sosial (BPJS) kesehatan in Indonesia, with restrictions (access approval no.:
- 413 510/PPID/1223). Data are available from the authors upon reasonable request and with
- 414 permission of the BPJS Kesehatan. The latter needs a request to the BPJS Kesehatan for
- 415 their sample dataset published in August 2019 via https://e-ppid.bpjs-kesehatan.go.id/.
- 416 The analytical codes are available at https://github.com/herdiantrisufriyana/fgr sga.

#### 417 **References**

- 418 [1] Fetal growth restriction: Acog practice bulletin, number 227. *Obstet Gynecol* 2021;**137**:e16-e28. doi: https://doi.org/10.1097/aog.000000000004251.
- 420 [2] Nardozza LM, Caetano AC, Zamarian AC, et al. Fetal growth restriction: Current knowledge. 421 *Arch Gynecol Obstet* 2017;**295**:1061-77. doi: https://doi.org/10.1007/s00404-017-4341-9.
- Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis. *Am J Obstet Gynecol* 2017;**216**:110-20.e6. doi: https://doi.org/10.1016/j.ajog.2016.09.076.
- Pedroso MA, Palmer KR, Hodges RJ, Costa FDS, Rolnik DL. Uterine artery doppler in screening for preeclampsia and fetal growth restriction. *Rev Bras Ginecol Obstet* 2018;**40**:287-93. doi: https://doi.org/10.1055/s-0038-1660777.
- 428 [5] Mallia T, Grech A, Hili A, Calleja-Agius J, Pace NP. Genetic determinants of low birth weight.
  429 *Minerva Ginecol* 2017;**69**:631-43. doi: https://doi.org/10.23736/s0026-4784.17.04050-3.
- 430 [6] Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: When? Where? Why? *Lancet* 2005;**365**:891-900. doi: https://doi.org/10.1016/s0140-6736(05)71048-5.
- 432 [7] Ausbeck EB, Allman PH, Szychowski JM, Subramaniam A, Katheria A. Neonatal outcomes at extreme prematurity by gestational age versus birth weight in a contemporary cohort. *Am J Perinatol* 2021;**38**:880-88. doi: https://doi.org/10.1055/s-0040-1722606.
- Tabet M, Flick LH, Xian H, Jen Jen C. Smallness at birth and neonatal death: Reexamining the current indicator using sibling data. *Am J Perinatol* 2021;**38**:76-81. doi:
- 437 https://doi.org/10.1055/s-0039-1694761.

- 438 [9] Lehtonen L, Gimeno A, Parra-Llorca A, Vento M. Early neonatal death: A challenge worldwide. 439 Semin Fetal Neonatal Med 2017;22:153-60. doi: https://doi.org/10.1016/j.siny.2017.02.006.
- 440 [10] Colella M, Frérot A, Novais ARB, Baud O. Neonatal and long-term consequences of fetal growth restriction. *Curr Pediatr Rev* 2018;**14**:212-18. doi: https://doi.org/10.2174/1573396314666180712114531.
- 443 [11] Umran RM, Al-Jammali A. Neonatal outcomes in a level ii regional neonatal intensive care unit. 444 *Pediatr Int* 2017;**59**:557-63. doi: https://doi.org/10.1111/ped.13200.
- Horbar JD, Edwards EM, Greenberg LT, et al. Racial segregation and inequality in the neonatal intensive care unit for very low-birth-weight and very preterm infants. *JAMA Pediatr* 2019;**173**:455-61. doi: https://doi.org/10.1001/jamapediatrics.2019.0241.
- 448 [13] Ho T, Zupancic JAF, Pursley DM, Dukhovny D. Improving value in neonatal intensive care.
  449 Clin Perinatol 2017;44:617-25. doi: https://doi.org/10.1016/j.clp.2017.05.009.
- 450 [14] Bettiol A, Avagliano L, Lombardi N, et al. Pharmacological interventions for the prevention of fetal growth restriction: A systematic review and network meta-analysis. *Clin Pharmacol Ther* 2021;**110**:189-99. doi: https://doi.org/10.1002/cpt.2164.
- 453 [15] Audette MC, Kingdom JC. Screening for fetal growth restriction and placental insufficiency. 454 Semin Fetal Neonatal Med 2018;23:119-25. doi: https://doi.org/10.1016/j.siny.2017.11.004.
- Luntsi G, Ugwu AC, Nkubli FB, Emmanuel R, Ochie K, Nwobi CI. Achieving universal access to obstetric ultrasound in resource constrained settings: A narrative review. *Radiography (Lond)* 2021;**27**:709-15. doi: https://doi.org/10.1016/j.radi.2020.10.010.
- 458 [17] Selvaratnam RJ, Wallace EM, Flenady V, Davey MA. Risk factor assessment for fetal growth restriction, are we providing best care? *Aust N Z J Obstet Gynaecol* 2020;**60**:470-73. doi: https://doi.org/10.1111/ajo.13147.
- Wagstaff A, Neelsen S. A comprehensive assessment of universal health coverage in 111 countries: A retrospective observational study. *Lancet Glob Health* 2020;**8**:e39-e49. doi: https://doi.org/10.1016/s2214-109x(19)30463-2.
- Andreasen LA, Tabor A, Nørgaard LN, et al. Why we succeed and fail in detecting fetal growth restriction: A population-based study. *Acta Obstet Gynecol Scand* 2021;**100**:893-99. doi: https://doi.org/10.1111/aogs.14048.
- 467 [20] Sufriyana H, Husnayain A, Chen YL, et al. Comparison of multivariable logistic regression and other machine learning algorithms for prognostic prediction studies in pregnancy care:

  469 Systematic review and meta-analysis. *JMIR Med Inform* 2020;**8**:e16503. doi: https://doi.org/10.2196/16503.
- 471 [21] Sufriyana H, Wu YW, Su EC. Artificial intelligence-assisted prediction of preeclampsia:
  472 Development and external validation of a nationwide health insurance dataset of the bpjs
  473 kesehatan in indonesia. *EBioMedicine* 2020;**54**:102710. doi:
  474 https://doi.org/10.1016/j.ebiom.2020.102710.
- 475 [22] Moons KG, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (tripod): Explanation and elaboration. *Ann Intern Med* 2015;**162**:W1-73. doi: https://doi.org/10.7326/m14-0698.
- 478 [23] Sufriyana H, Wu YW, Su EC-Y. Human and machine learning pipelines for responsible clinical prediction using high-dimensional data. *Protocol Exchange* 2021. doi: https://doi.org/10.21203/rs.3.pex-1655/v1.
- 481 [24] Ariawan I, Sartono B, Jaya C. Sample dataset of the bpjs kesehatan 2015-2016. Jakarta BPJS Kesehatan; 2019.
- 483 [25] Moraffah R, Karami M, Guo R, Raglin A, Liu H. Causal interpretability for machine learning-484 problems, methods and evaluation. *ACM SIGKDD Explorations Newsletter* 2020;**22**:18-33. doi, 485 PMID.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The prisma 2020 statement: An updated guideline for reporting systematic reviews. *Bmj* 2021;**372**:n71. doi: https://doi.org/10.1136/bmj.n71.
- Shlossman P, Scisione A, Manley J, Colmorgen G, Weiner S. Doppler assessment of the intrafetal vasculature in the identification of intrauterine growth retardation. Which vessel is 'best' or is a combination better? *American Journal of Obstetrics & Gynecology* 1998;**178**:S88. doi: https://doi.org/10.1016/j.ajog.2012.01.022.
- 492 [28] Bednarek M, Dubiel M, Brêborowicz GH. P05.18: Doppler velocimetry in m1 and m2 segments of middle cerebral artery in pregnancies complicated by intrauterine growth restriction.

  494 Ultrasound in Obstetrics & Gynecology 2004;24:300-01. doi:
- 495 https://doi.org/https://doi.org/10.1002/uog.1423.

$^{\circ}$	1	٦
$\mathcal{L}$	ı	J

496	[29]	Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical
497		markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound</i>
498		Obstet Gynecol 2016;47:194-202. doi: https://doi.org/10.1002/uog.14928.
499	[30]	Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH. Reference range of birth
500		weight with gestation and first-trimester prediction of small-for-gestation neonates. <i>Prenat</i>
501		Diagn 2011; <b>31</b> :58-65. doi: https://doi.org/10.1002/pd.2520.

- 502 [31] Bano S, Chaudhary V, Pande S, Mehta V, Sharma A. Color doppler evaluation of cerebral-503 umbilical pulsatility ratio and its usefulness in the diagnosis of intrauterine growth retardation 504 and prediction of adverse perinatal outcome. *Indian J Radiol Imaging* 2010;**20**:20-5. doi: 505 https://doi.org/10.4103/0971-3026.59747.
- 506 [32] Carbone JF, Tuuli MG, Bradshaw R, Liebsch J, Odibo AO. Efficiency of first-trimester growth restriction and low pregnancy-associated plasma protein-a in predicting small for gestational age at delivery. *Prenat Diagn* 2012;**32**:724-9. doi: https://doi.org/10.1002/pd.3891.
- 509 [33] Leung TY, Sahota DS, Chan LW, et al. Prediction of birth weight by fetal crown-rump length and maternal serum levels of pregnancy-associated plasma protein-a in the first trimester.

  511 Ultrasound Obstet Gynecol 2008;31:10-4. doi: https://doi.org/10.1002/uog.5206.
- 512 [34] Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein a, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. *Am J Obstet Gynecol* 2004;**191**:1452-8. doi: https://doi.org/10.1016/j.ajog.2004.05.068.
- 516 [35] Zhou Q, Chen ZH, Cao YH, Peng S. Clinical impact and quality of randomized controlled trials
   517 involving interventions evaluating artificial intelligence prediction tools: A systematic review.
   518 NPJ Digit Med 2021;4:154. doi: https://doi.org/10.1038/s41746-021-00524-2.
   519

**Figure Captions** 520 Figure 1. Subject selection by applying a retrospective design and data partitioning 521 for internal and external validations. The set for association tests included censored 522 523 outcomes. The summation of the internal and external validation numbers differs from 524 the total because: (1) there were subject overlaps; (2) the numbers of subjects and visits 525 in the censored internal validation are not shown; and (3) we excluded subjects with no pregnancy before data analysis. <sup>a</sup>, the first and second pregnancies of a subject within the database period, not parity; <sup>b</sup>, subjects per pregnancy episode; <sup>c</sup>, only subjects in the 526 527 external random split overlapped with those in the internal validation sets; n, sample 528 529 size; (?), number of censoring; (–), number of nonevents; (+), number of events. 530 Figure 2. Model calibration (a) and clinical utility (b). We evaluated both using a 531 calibration split (i.e., ~20% of internal validation set) within the optimal range of 532 predicted probabilities (equivalent to thresholds) across all of the models. This figure 533 shows only the well-calibrated models. Solid lines with gray shading show the 534 regression line and standard errors over point estimates of true probabilities. Dotted lines show a threshold of 95% specificity. CI, confidence interval; DI-VNN, deep-535 536 insight visible neural network; ENR, elastic net regression; GBM, gradient boosting 537 machine; PC, principal component. 538 Figure 3. Model discrimination by receiver operating characteristics (ROC) curves. 539 The evaluation used a calibration split (i.e., ~20% of the internal validation set) for only 540 the well-calibrated models. The vertical dotted lines show 95% specificity, while the 541 diagonal dotted lines show the area under the ROC curve (AUROC) of 0.5 as a 542 reference, DI-VNN, deep-insight visible neural network; ENR, elastic net regression; 543 GBM, gradient boosting machine; PC, principal components. 544 Figure 4. Model discrimination by the area under the receiver operating 545 **characteristics curves (AUROCs).** This figure shows only the well-calibrated models. 546 The vertical dotted lines show AUROCs of 0.5 and the averages using internal 547 calibration split, training set, and external random and non-random splits. See Appendix 548 D for details of eligible models from previous studies. If any predictor list of these 549 models is too long, then it is truncated by "...". βhCG, β-subunit human 550 choriogonadotropin; BMI, body-mass index; Cig., cigarette; CRL, crown-rump length 551 (fetus); CU-R, cerebral-umbilical ratio; DI-VNN, deep-insight visible neural network; 552 EFW, estimated fetal weight; ENR, elastic net regression; GBM, gradient boosting 553 machine; ICA, internal carotid artery; MCA, middle cerebral artery; NT, nuchal 554 translucency thickness (fetus); PAPP-A, pregnancy-associated plasma protein-A; PC, 555 principal component; PIGF, placental growth factor; PI, pulsatility index; RA, renal 556 artery; RI, resistance index; ROC, receiver operating characteristics; SD, systolic-557 diastolic ratio; sFLT-1, soluble fms-like tyrosinase-1; UA, umbilical artery; UtA,

558

uterine artery.

Variable		Not FGR/SGA <sup>a</sup> ( <i>n</i> =26,459)	FGR/SGA <sup>a</sup> (n=117)	p value
Pregnancy episode	First pregnancy, <sup>c</sup> no. (%)	25,096 (94.85)	109 (93.16)	(reference)
within database period <sup>b</sup>	Second pregnancy, <sup>c</sup> no. (%)	1363 (5.15)	8 (6.84)	0.41
Maternal age	Mean (SD), year	29 (6)	28 (6)	0.006**
Insurance class	First, no. (%)	3604 (13.62)	21 (17.95)	(reference)
	Unspecified, no. (%)	87 ( 0.33)	1 ( 0.85)	0.51
	Second, no. (%)	9226 (34.87)	50 (42.74)	0.78
	Third, no. (%)	13,542 (51.18)	45 (38.46)	0.03*
Marital status	Married, no. (%)	16,831 (63.61)	77 (66)	(reference)
	Single, no. (%)	2397 ( 9.06)	20 (17)	0.02*
	Unspecified, no. (%)	7117 (26.90)	20 (17)	0.05
	Divorced/widowed, no. (%)	114 ( 0.43)	77 (66)	0.97
Occupation	Central-government employee, no. (%)	7683 (29.04)	20 (17.1)	(reference)
segment of the householder	Private company employee, no. (%)	9611 (36.32)	57 (48.7)	0.002**
nousenoidei	Private company employer or self-	7871 (29.75)	35 (29.9)	0.06
	employed, no. (%) Local-government employee, no. (%)	1278 ( 4.83)	5 ( 4.3)	0.42
	Unemployed, no. (%)	16 ( 0.06)	5 ( 4.3)	0.98
Pregnancy-induced	Negative, no. (%)	25,366 (9.6e-01)	98 (8.4e-01)	(reference)
hypertension	Positive, no. (%)	1093 (4.1e-02)	19 (1.6e-01)	<0.001***
Multiple	Negative, no. (%)	26,271 (9.9e-01)	112 (9.6e-01)	(reference)
pregnancies	Positive, no. (%)	188 (7.1e-03)	5 (4.3e-02)	<0.001***
Malaria	Negative, no. (%)	26,439 (1.0e+00)	117 (1.0e+00)	(reference)
	Positive, no. (%)	20 (7.6e-04)	0 (0.0e+00)	<0.001***
Varicella	Negative, no. (%)	26,446 (1.0e+00)	117 (1.0e+00)	(reference)
	Positive, no. (%)	13 (4.9e-04)	0 (0.0e+00)	<0.001***
Risk of adverse	Negative, no. (%)	19,660 (7.4e-01)	93 (7.9e-01)	(reference)
pregnancy by maternal age Urinary tract infection	Positive, no. (%)	6799 (2.6e-01)	24 (2.1e-01)	<0.001***
	Negative, no. (%)	26,294 (9.9e-01)	116 (9.9e-01)	(reference)
	Positive, no. (%)	165 (6.2e-03)	1 (8.5e-03)	<0.001***
Placenta previa	Negative, no. (%)	26,187 (9.9e-01)	113 (9.7e-01)	(reference)
	Positive, no. (%)	272 (1.0e-02)	4 (3.4e-02)	<0.001***
Low	Negative, no. (%)	12,901 (4.9e-01)	72 (6.2e-01)	(reference)
socioeconomic status	Positive, no. (%)	13,558 (5.1e-01)	45 (3.8e-01)	0.05*

This table shows only latent candidate predictors with significant associations by multivariate analyses (Table 2). \*  $p \le 0.05$ ; \*\*\*  $p \le 0.01$ ; \*\*\*  $p \le 0.001$ ; a, Subject per pregnancy episode (not including censored delivery); b, Not FGR/SGA vs. FGR/SGA (not including those who were not pregnant); c, The first and second pregnancies of a subject within the database period; FGR, fetal growth restriction; SGA, small for gestational age; SD, standard deviation.

Variable of interest	Unadjusted OR (95% CI; p value)	Adjusted OR (95% CI; p value)	Adjustment
Pregnancy-induced hypertension	1.012 (1.011 to 1.013; <i>p</i> <0.001***)	1.007 (1.007 to 1.008; <i>p</i> <0.001***)	Multiple pregnancies +
nypercusion			Risk of adverse pregnancy by
			maternal age
Multiple pregnancies	1.051 (1.047 to 1.054; <i>p</i> <0.001***)	1.048 (1.044 to 1.052; p<0.001***)	Risk of adverse pregnancy by maternal age
Malaria	0.993 (0.993 to 0.993; p<0.001***)	0.993 (0.993 to 0.993; p<0.001***)	Low socioeconomic status
Varicella	0.993 (0.993 to 0.993; <i>p</i> <0.001***)	0.993 (0.993 to 0.993; <i>p</i> <0.001***)	(no adjustment)
Risk of adverse pregnancy by maternal age	0.996 (0.996 to 0.996; p<0.001***)	0.996 (0.996 to 0.996; p<0.001***)	(no adjustment)
Urinary tract infection	1.068 (1.064 to 1.073; p<0.001***)	1.137 (1.128 to 1.146; <i>p</i> <0.001***)	Risk of adverse pregnancy by maternal age
Placenta previa	1.028 (1.026 to 1.031; <i>p</i> <0.001***)	1.022 (1.02 to 1.024; p<0.001***)	Risk of adverse pregnancy by maternal age
Low socioeconomic status	0.999 (0.999 to 1; p=0.05*)	0.999 (0.999 to 1; p=0.05*)	(no adjustment)

<sup>\*</sup>  $p \le .05$ ; \*\*\*  $p \le .01$ ; \*\*\*  $P \le .001$ ; CI, confidence interval; OR, odds ratio.

565

566

567

Model	Top-five predictor	PN (95% CI)	PS (95% CI)	Clinician 1	Clinician 2
DI-VNN a, b	M791, Myalgia	97.63%	1.7%	Plausible	Implausible, only a
		(97.51% to 97.76%)	(1.7% to 1.71%)		general symptom
	O141, Severe	98.57%	2.08%	Implausible	Plausible, especially
	preeclampsia	(98.5% to 98.63%)	(2.07% to 2.09%)		early-onset preeclampsia
	O410,	98.22%	1.34%	Plausible	Plausible
	Oligohydramnios	(98.11% to 98.33%)	(1.33% to 1.34%)		
	O470, False labor	98.41%	0.59%	Plausible	Plausible
	before 37 completed weeks of gestation	(98.15% to 98.67%)	(0.59% to 0.59%)		
	O48, Prolonged	98.33%	0.82%	Plausible	Implausible, FGR/SGA
	pregnancy	(98.18% to 98.48%)	(0.82% to 0.82%)	Tausioic	mostly preterm and
	pregnancy	(70.10% to 70.40%)	(0.02/0 to 0.02/0)		term
PC-ENR b	Placenta previa <sup>c</sup>	98.2%	8.39%	Implausible	Plausible
i e Eivit	r meema previa	(98.15% to 98.25%)	(8.39% to 8.39%)	Implausiole	1 Russole
	E86, Volume	98.08%	8.44%	Implausible	Plausible
	depletion	(97.93% to 98.22%)	(8.44% to 8.44%)	impiausioie	1 14451010
	K021, Caries of	99.9%	9.31%	Implausible	Plausible
	dentine	(99.88% to 99.91%)	(9.3% to 9.32%)	P	
	O410,	98.4%	8.47%	Implausible	Plausible
	Oligohydramnios	(98.32% to 98.49%)	(8.47% to 8.47%)	1	
	O624, Hypertonic,	99.43%	8.44%	Implausible	Implausible, after
	uncoordinated, and prolonged uterine contractions	(99.37% to 99.49%)	(8.44% to 8.44%)	1	FGR/SGA onset and only during labor
PC-GBM	Urinary tract	98.96%	5.7%	Implausible	Plausible
i C-GDIVI	infection <sup>c</sup>	(98.85% to 99.06%)	(5.68% to 5.71%)	Implausioic	1 lausible
	E282, Polycystic	99.82%	2.34%	Implausible	Plausible, PCOS
	ovarian syndrome	(99.79% to 99.85%)	(2.34% to 2.34%)	Implausioic	mostly with infertility
	ovarian syndrome	()).1)/0 (0)/).03/0)	(2.5470 to 2.5470)		which is likely
					undergoing ovarian
					stimulation,
					subsequently resulting
					in twin pregnancy and
					FGR/SGA
	E86, Volume	99.08%	16.46%	Implausible	Plausible
	depletion	(98.97% to 99.19%)	(16.43% to 16.49%)	1	
	N832, Other and	98.68%	8.22%	Implausible	Implausible, only large-
	unspecified ovarian	(98.51% to 98.86%)	(8.2% to 8.24%)		size cysts compete with
	cysts				fetal growth, yet,
					unspecified cysts are
					likely small, corpus-
					luteum cysts
	Z349, Supervision	98.65%	1.76%	Implausible	Implausible, no risk of
	of normal pregnancy,	(98.61% to 98.7%)	(1.76% to 1.77%)		FGR/SGA in normal pregnancy
	unspecified				

The clinicians assessed only the well-calibrated models without information on the predictive performances; the top-five predictors had either a top probability of necessity (PN) or probability of sufficiency (PS); <sup>a</sup>, chosen by clinician 1; <sup>b</sup>, chosen by clinician 2; <sup>c</sup>, latent predictor (see Table 2). CI, confidence interval; DI-VNN, deep-insight visible neural network; ENR, elastic net regression; FGR, fetal growth restriction; GBM, gradient boosting machine; PC, principal component; PCOS, polycystic ovarian syndrome; PN, probability of necessity (probability of predicted outcomes would have been nonevents among samples with a positive predictor and an event if changing the predictor to negative); PS, probability of sufficiency (probability of predicted outcomes would have been events among samples with a negative predictor and a nonevent if changing the predictor to positive); SGA, small for gestational age.







